Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Gina Love-Walker

Internal Medicine Columbus, OH Medical Doctor

NPI 1154319622 CMS profile 278808

170 Taylor Station Rd, Suite 210, Columbus, OH 43213

Open in the dashboard

General payments

$14,855

596 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Gina Love-Walker of Columbus, OH is reported in the CMS Open Payments database as having received $14,855 across 596 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,440 70
2024 General $2,328 84
2023 General $2,283 96
2022 General $2,175 89
2021 General $1,528 71
2020 General $1,141 65
2019 General $2,960 121

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Gina Love-Walker
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Gina Love-Walker were reported at $2,440. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Gina Love-Walker Internal Medicine median Middle half National median
2019 $2,960 $159 $48–$570 $163
2020 $1,141 $119 $33–$402 $114
2021 $1,528 $135 $37–$521 $132
2022 $2,175 $141 $42–$496 $149
2023 $2,283 $149 $45–$519 $160
2024 $2,328 $154 $47–$537 $164
2025 $2,440 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Amgen Inc. $2,891 128 payments
  2. AbbVie, Inc. $2,179 105 payments
  3. AstraZeneca Pharmaceuticals LP $1,820 47 payments
  4. Novo Nordisk Inc $1,740 63 payments
  5. Abbott Laboratories $944 30 payments
  6. Amarin Pharma Inc. $835 57 payments
  7. Lilly USA, LLC $678 24 payments
  8. Astellas Pharma US Inc $497 10 payments
  9. Allergan Inc. $471 21 payments
  10. Pfizer Inc. $428 14 payments
  11. Other $2,371 97 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $14,553 588 payments
  2. Education $298 6 payments
  3. Travel and Lodging $4 2 payments
Products named General payments · program years 2019–2025
  1. UBRELVY $1,550 65 payments
  2. QULIPTA $1,261 62 payments
  3. EVENITY $1,079 65 payments
  4. Prolia $919 63 payments
  5. Repatha $890 38 payments
  6. AIRSUPRA $830 11 payments
  7. Ozempic $737 21 payments
  8. FARXIGA $671 32 payments
  9. FreeStyle Libre 2 $532 18 payments
  10. Wegovy $500 20 payments
  11. Other $7,920 344 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 36 drugs

Part D claims

598

Median for Internal Medicine: 777

Drug cost

$87,835

Median for Internal Medicine: $73,373

Branded share of claims

25.3%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Farxiga Dapagliflozin Propanediol Brand 19 $18,326
Mounjaro Tirzepatide Brand 13 $15,267
Ozempic Semaglutide Brand 14 $13,340
Eliquis Apixaban Brand 15 $10,495
Myrbetriq Mirabegron Brand 12 $7,178
Veozah Fezolinetant Brand 11 $5,712
Belsomra Suvorexant Brand 11 $4,799
Vascepa Icosapent Ethyl Brand 11 $3,518
Synthroid Levothyroxine Sodium Brand 14 $1,719
Memantine Hcl Generic 14 $1,560

The 10 drugs with the highest cost, of 36 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 24 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $352
$352 — —
UBRELVY
  • AbbVie, Inc. $319
$319 — —
Wegovy
  • Novo Nordisk Inc $209
$209 — —
QULIPTA
  • AbbVie, Inc. $181
$181 — —
Sunosi
  • Axsome Therapeutics, Inc. $121
$121 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 24 in the dashboard with a free account

Records

596 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record